

De-risking early stage drug discovery and developing novel drugs



Developing small molecule and therapeutic antibody programs with academia

Collaborating with industry on their in-house drug discovery programs

pharma/biotech opportunities

as a scientific collaborator

- Opportunity to exclusively work on an early stage, less validated target of interest at CTD's cost and risk
- Opportunity to reignite early stage program stalled due to internal prioritization/resource decisions
- Share costs thereby reduce costs on early stage medicinal chemistry collaboration
- Exclusive option to take the program back in-house at any stage

as a licensee to small molecules and therapeutic antibodies


- Novel approaches to drug discovery with early stage risk removed
- 'Ready to Run' HTS assays
- Characterized targets with supporting biology & associated scientific expertise
- Hit or Lead compounds for initiation of clinical candidate chemistry
- Humanized antibodies - *in vivo* trial ready
- Proven antibody engineering experience

academic and not for profit partners

enhanced R&D capabilities
commercial programs to
protect IP & create revenue

the MRCT
drug discovery
process

- Collaborating with assay development, medicinal chemistry and/or antibody engineering teams, including out-sourced expertise
- Access to specialized resources & equipment
- Compounds/Antibodies re-supplied as 'research tools' and for target validation studies
- Pre-publication IP verifying, patent filing and asset management
- Revenue sharing agreement



Work with established world leading teams who have proven expertise in:

Early stage small molecule drugs

Therapeutic antibodies

our teams are experts in

small molecule **drug discovery** development

humanizing antibodies

- Medicinal Chemistry – Extensive Pharma background
- Screening and Hit Profiling - High versatility
- Working on small molecule projects for the past 4.5 years
- Several programs underway
- First program partnered with Genentech in May 2010

- Therapeutic Antibody Group – World leaders in humanization for over 20 years
- 45+ humanized for, and/or partnered with Pharma/Biotech
- 12 recombinant antibodies have progressed to the clinic
- 8 are currently in active clinical development
- 2 humanized antibodies have secured marketing approval: Actemra® and Tysabri®

info@tech.mrc.ac.uk

we are looking for new commercial and academic partners

Pharma/Biotech let us develop your work

Projects can be early stage, need further validation or be stalled projects you wish to exploit further.

To discuss your company's needs please contact info@tech.mrc.ac.uk or call us on +44 (0)20 7391 2798

Tech Transfer Offices and Academic Organisations Let us help develop and commercialize your portfolio of targets

To discuss joint development opportunities please call or email us:

e-mail: targets@tech.mrc.ac.uk
telephone: +44 (0)20 7391 2826

Academic Researchers let us develop your work

Your research may have the potential to become a small molecule drug project or therapeutic antibody. Targets should have a clear unmet medical need and be a novel target with some validation/link to disease.

Do you need an inhibitor or activator of the target? CTD will cover all CTD costs and risks.

We are happy to work with collaborators to attract grant funding if required.

Individual researchers should visit www.callfortargets.org to download a target submission form.

callfortargets.org
mrctechnology.org

about MRC Technology

MRC Technology develops and licenses cutting edge scientific research into commercial products, in order to benefit healthcare. We are the **exclusive agent** for the UK's **Medical Research Council** and have filed 300+ patents, granted 300+ licenses and generated over **US\$800m/GBP£500m** to fund further research.

Our recently formed **Centre for Therapeutics Discovery** (CTD) focuses on 'own risk' (commercial) drug development projects for small molecules and monoclonal antibodies and works with Biotech/Pharma on collaborative research programs. The CTD team comprises of mostly industry recruited scientists including, 15 medicinal chemists, 2 computational chemists, 2 analytical and *in-vitro* DMPK specialists, 17 assay development, screening scientists and cell pharmacologists and 10 antibody scientists (forming the Therapeutic Antibody Group).

We have access to large **Compound collections**

- 100,000 compound Diversity set
- 14,000 compound alpha helix mimetic set
- 7,000 compound kinase set
- 4000 natural products
- 3000 pharmacologically active tool set
- 1000 fragment screening set
- Access to AstraZeneca's compound libraries

MRC TECHNOLOGY Lynton House 7-12 Tavistock Square London WC1H 9LT United Kingdom
Tel +44 (0)20 7391 2700 Fax +44 (0)20 7391 2800 info@mrc.tech.ac.uk mrctechnology.org

Medical Research Council Technology is a company limited by guarantee no. 2698321, incorporated in England and a charity registered in England and Wales no. 1015243, and a charity registered in Scotland no. SC037861. Registered office: Lynton House, 7-12 Tavistock Square, London WC1H 9LT, UK. All details correct at time of production, November 2010, E&OE.